|
|
Volumn 3, Issue 4, 2011, Pages
|
|
Bispecific antibodies and ADCs: Once and future kings?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIBODY CONJUGATE;
BISPECIFIC ANTIBODY;
BRENTUXIMAB VEDOTIN;
CATUMAXOMAB;
GEMTUZUMAB OZOGAMICIN;
INOTUZUMAB OZOGAMICIN;
TRASTUZUMAB EMTANSINE;
AMINOGLYCOSIDE;
ANTINEOPLASTIC AGENT;
GEMTUZUMAB;
MONOCLONAL ANTIBODY;
ANTIGEN BINDING;
BREAST CANCER;
DRUG CONJUGATION;
DRUG RESEARCH;
EDITORIAL;
FOLLICULAR LYMPHOMA;
HODGKIN DISEASE;
LARGE CELL LYMPHOMA;
CLINICAL TRIAL (TOPIC);
HUMAN;
IMMUNOLOGY;
IMMUNOTHERAPY;
NEOPLASM;
AMINOGLYCOSIDES;
ANTIBODIES, BISPECIFIC;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS AS TOPIC;
HUMANS;
IMMUNOCONJUGATES;
IMMUNOTHERAPY;
NEOPLASMS;
|
|
EID: 79960107245
PISSN: 19420862
EISSN: 19420870
Source Type: Journal
DOI: 10.4161/mabs.3.4.16589 Document Type: Editorial |
|
Times cited : (16)
|
|
References (0)
|
